WO1997025071A3 - Immunoconjugues pour le traitement du sida - Google Patents

Immunoconjugues pour le traitement du sida Download PDF

Info

Publication number
WO1997025071A3
WO1997025071A3 PCT/US1997/000476 US9700476W WO9725071A3 WO 1997025071 A3 WO1997025071 A3 WO 1997025071A3 US 9700476 W US9700476 W US 9700476W WO 9725071 A3 WO9725071 A3 WO 9725071A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
immunoconjugate
aids
immunoconjugates
subunits
Prior art date
Application number
PCT/US1997/000476
Other languages
English (en)
Other versions
WO1997025071A2 (fr
WO1997025071A9 (fr
Inventor
Fatih M Uckun
Original Assignee
Univ Minnesota
Fatih M Uckun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Fatih M Uckun filed Critical Univ Minnesota
Priority to AU16971/97A priority Critical patent/AU1697197A/en
Priority to EP97902907A priority patent/EP0873140A2/fr
Priority to JP9525440A priority patent/JP2000505076A/ja
Publication of WO1997025071A2 publication Critical patent/WO1997025071A2/fr
Publication of WO1997025071A3 publication Critical patent/WO1997025071A3/fr
Publication of WO1997025071A9 publication Critical patent/WO1997025071A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des immunoconjugués comportant l'anticorps monoclonal TXU-5-B53 lié à une protéine antivirale de la morelle à grappes ou des unités bioactives de ladite protéine, efficaces pour le traitement de l'infection à VIH des mammifères.
PCT/US1997/000476 1996-01-11 1997-01-10 Immunoconjugues pour le traitement du sida WO1997025071A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU16971/97A AU1697197A (en) 1996-01-11 1997-01-10 Immunoconjugate for the treatment of aids
EP97902907A EP0873140A2 (fr) 1996-01-11 1997-01-10 Immunoconjugues pour le traitement du sida
JP9525440A JP2000505076A (ja) 1996-01-11 1997-01-10 エイズ治療用免疫複合体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/584,966 1996-01-11
US08/584,966 US5919457A (en) 1996-01-11 1996-01-11 TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS

Publications (3)

Publication Number Publication Date
WO1997025071A2 WO1997025071A2 (fr) 1997-07-17
WO1997025071A3 true WO1997025071A3 (fr) 1997-10-16
WO1997025071A9 WO1997025071A9 (fr) 1997-11-13

Family

ID=24339486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000476 WO1997025071A2 (fr) 1996-01-11 1997-01-10 Immunoconjugues pour le traitement du sida

Country Status (6)

Country Link
US (1) US5919457A (fr)
EP (1) EP0873140A2 (fr)
JP (1) JP2000505076A (fr)
AU (1) AU1697197A (fr)
CA (1) CA2242514A1 (fr)
WO (1) WO1997025071A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372217B1 (en) 1997-06-03 2002-04-16 Regents Of The University Of Minnesota Methods for the treatment of CD7+ viral infection with TXU-7-PAP
WO2003106479A2 (fr) * 2002-06-17 2003-12-24 Parker Hughes Institute Polypeptides de proteine antivirale de phytolaque a activite antivirale
US6936288B2 (en) * 2003-06-10 2005-08-30 Klearsen Corporation Method and composition for the treatment of shingles and related afflictions
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381763A1 (fr) * 1988-06-10 1990-08-16 Shuzo Matsushita Anticorps modifie par une toxine
WO1991001145A1 (fr) * 1989-07-25 1991-02-07 Regents Of The University Of Minnesota Conjugues de proteines antivirales pokeweed - anticorps monoclonaux
WO1996038751A2 (fr) * 1995-06-01 1996-12-05 Minnesota Mining And Manufacturing Company Cable-ruban de fibre optique et procede de fabrication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381763A1 (fr) * 1988-06-10 1990-08-16 Shuzo Matsushita Anticorps modifie par une toxine
WO1991001145A1 (fr) * 1989-07-25 1991-02-07 Regents Of The University Of Minnesota Conjugues de proteines antivirales pokeweed - anticorps monoclonaux
WO1996038751A2 (fr) * 1995-06-01 1996-12-05 Minnesota Mining And Manufacturing Company Cable-ruban de fibre optique et procede de fabrication

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ERICE, ALEJO ET AL: "Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein", ANTIMICROB. AGENTS CHEMOTHER. (1993), 37(4), 835-8 CODEN: AMACCQ;ISSN: 0066-4804, 1993, XP002037547 *
F.M. UCKUN ET AL.: "EFFECTIVE IMMUNOCHEMOTHERAPY OF CALL+Cmu+ Human PRE-B ACUTE LYMPHOBLASTIC LEUKEMIA IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY USING B43 (ANTI-CD19) POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN PLUS CYCLOPHOSPHAMIDE.", BLOOD, vol. 79, no. 12, 15 June 1992 (1992-06-15), pages 3116 - 3129, XP002037546 *
MYERS, DOROTHEA E. ET AL: "Production of a pokeweed antiviral protein ( PAP )-containing immunotoxin, B43- PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials", J. IMMUNOL. METHODS (1991), 136(2), 221-38 CODEN: JIMMBG;ISSN: 0022-1759, 1991, XP002037544 *
ZARLING, JOYCE M. ET AL: "Inhibition of HIV -1 replication in seropositive patients' CD4+ T-cells by pokeweed antiviral protein-monoclonal antibody conjugates", INT. J. IMMUNOPHARMACOL. (1991), 13(SUPPL. 1), 63-8 CODEN: IJIMDS;ISSN: 0192-0561, 1991, XP002037548 *
ZARLING, JOYCE M. ET AL: "Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies", NATURE (LONDON) (1990), 347(6288), 92-5 CODEN: NATUAS;ISSN: 0028-0836, 1990, XP002037545 *

Also Published As

Publication number Publication date
AU1697197A (en) 1997-08-01
EP0873140A2 (fr) 1998-10-28
US5919457A (en) 1999-07-06
WO1997025071A2 (fr) 1997-07-17
JP2000505076A (ja) 2000-04-25
CA2242514A1 (fr) 1997-07-17

Similar Documents

Publication Publication Date Title
WO1998055150A8 (fr) Immunotoxine txu-7-pap et utilisation de cette immunotoxine
IL189629A0 (en) Compositions containing human ctla-4 antibodies
WO1997025071A3 (fr) Immunoconjugues pour le traitement du sida
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ES2191075T3 (es) 8-arilalquil- y 8-arilheteroalquil-5,11-dihidro-6h-dipirido-(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infecciones por hiv.
HUP9903420A3 (en) Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections
ITFI920078A0 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umana.
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
AU2784792A (en) Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv
AU7160691A (en) Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
WO2001040473A3 (fr) Antigenes de pseudomonas aeruginosa
AU5758594A (en) Treatment of viral infections
FI944561A0 (fi) HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV-infektion ehkäisemiseksi ja hoitamiseksi
PT633928E (pt) Microrganismos processo de preparacao e utilizacao
FR2695406B1 (fr) Procede de preparation de conjugues facteur intrinseque-peroxydase de raifort, conjugues ainsi obtenus et kits les contenant.
EP0655919A4 (fr) Traitement d'infections virales chez l'homme.
CA2088370A1 (fr) Utilisation d'anticorps monoclonaux
EP0450573A3 (fr) Anticorps pour le traitement et le diagnostic d'infections de Pseudomonas aeruginosa
AU4930300A (en) Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
EP0243174A3 (fr) Anticorps monoclonaux contre une exo-enzyme S de Pseudomonas aeruginosa, leur préparation et leur utilisation
FR2774863B1 (fr) Dispositif pour la fabrication de preparations culinaires dites aumonieres
ITRM950102V0 (it) Dispositivo ottico per l'osservazione di gemme.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2242514

Country of ref document: CA

Ref country code: CA

Ref document number: 2242514

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997902907

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997902907

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997902907

Country of ref document: EP